Fairvalue-Calculator Fairvalue-Calculator
EN DE

Radnostix, Inc (INIS) Fair Value & Analysis

Healthcare · US · Market cap $37.0M

Price$0.0800
Fair Value$0.0300
Upside-62.5%
Quality95/100
Evidence: Low Range $0.0200 – $0.0400

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Radnostix, Inc (INIS) currently trades at $0.0800, while our model-based Fair Value estimate is $0.0300 — implying the stock looks roughly 62.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Radnostix, Inc. manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, sodium iodide I-131 drug product, and radiochemicals for clinical research and life sciences in the United States and internationally. It operates through five segments: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products. The Theranostics Products segment produces and distributes Iodine-131 generic drug product and various isotopically pure radiochemicals for medical, industrial, and research applications. The Cobalt Products segment produces cobalt-60 products and services, the fabrication of cobalt-60 sealed sources for radiation therapy, industrial and medical applications, and recycling of expended cobalt-60 sources. The Calibration & Reference Products segment manufactures sources and standards associated with single photon emission computed and positron emission tomography imaging, patient positioning, an…

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +1949% Jiangsu Hengrui Pharmaceuticals Co (600276) -46% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -74% Hansoh Pharmaceutical Group (3692) -47% Divi's Laboratories Limited (DIVISLAB) -70%

Frequently asked questions

Is Radnostix, Inc (INIS) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $0.0300 versus a price of $0.0800 — about −63% (overvalued). Model-based estimate, not financial advice.
What is the fair value of INIS?
Our 21-model fair value for Radnostix, Inc is $0.0300 (as of Jun 24, 2026), built from audited fundamentals. The current price is $0.0800.
What is the quality score of INIS?
Radnostix, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.